<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Pharmateca</journal-id><journal-title-group><journal-title xml:lang="en">Pharmateca</journal-title><trans-title-group xml:lang="ru"><trans-title>Фарматека</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2073-4034</issn><issn publication-format="electronic">2414-9128</issn><publisher><publisher-name xml:lang="en">Bionika Media</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">456426</article-id><article-id pub-id-type="doi">10.18565/pharmateca.2023.3.90-98</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Age-dependent aspects of informativeness of surrogate indices of insulin resistance in the formation of menopausal metabolic syndrome</article-title><trans-title-group xml:lang="ru"><trans-title>Возраст-зависимые аспекты информативности суррогатных индексов инсулинорезистентности при формировании менопаузального метаболического синдрома</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6762-5238</contrib-id><name-alternatives><name xml:lang="en"><surname>Ruyatkina</surname><given-names>Lyudmila A.</given-names></name><name xml:lang="ru"><surname>Руяткина</surname><given-names>Людмила Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med.), Professor, Novosibirsk State Medical University, Novosibirsk, Russia</p></bio><bio xml:lang="ru"><p>д.м.н., профессор, Новосибирский государственный медицинский университет, Новосибирск</p></bio><email>larut@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3431-5943</contrib-id><name-alternatives><name xml:lang="en"><surname>Ruyatkin</surname><given-names>D. S.</given-names></name><name xml:lang="ru"><surname>Руяткин</surname><given-names>Д. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>larut@list.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9270-9188</contrib-id><name-alternatives><name xml:lang="en"><surname>Shcherbakova</surname><given-names>L. V.</given-names></name><name xml:lang="ru"><surname>Щербакова</surname><given-names>Л. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>larut@list.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Novosibirsk State Medical University</institution></aff><aff><institution xml:lang="ru">Новосибирский государственный медицинский университет</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Research Institute of Therapy and Preventive Medicine - Branch Campus of the Federal Research Center, Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт терапии и профилактической медицины – филиал ФГБНУ «Федеральный исследовательский центр, Институт цитологии и генетики Сибирского отделения Российской академии наук»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2023-05-23" publication-format="electronic"><day>23</day><month>05</month><year>2023</year></pub-date><volume>30</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>90</fpage><lpage>98</lpage><history><date date-type="received" iso-8601-date="2023-05-23"><day>23</day><month>05</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-05-23"><day>23</day><month>05</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Bionika Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО «Бионика Медиа»</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Bionika Media</copyright-holder><copyright-holder xml:lang="ru">ООО «Бионика Медиа»</copyright-holder></permissions><self-uri xlink:href="https://journals.eco-vector.com/2073-4034/article/view/456426">https://journals.eco-vector.com/2073-4034/article/view/456426</self-uri><abstract xml:lang="en"><p><bold><italic>Background.</italic></bold><italic> The need to assess insulin resistance (IR), which pathogenetically combines the components of the metabolic syndrome (MS), is of particular importance during its formation during the menopausal transition due to changes in the functional state of the pituitary–ovarian axis. In addition to the traditional indices of the HOMA family, the TyG index has attracted attention in recent years as surrogate indicator, showing close agreement with the clamp test, the gold standard for assessing the severity of IR. However, comparative studies of the informativity of surrogate insulin and non-insulin indices in the perimenopausal period are practically absent.</italic></p> <p><bold><italic>Objective.</italic></bold><italic> Evaluation of the effect of age on the relationship of surrogate indices of IR, TyG, and the HOMA2 family with the parameters of menopausal MS during its formation in a cohort of women aged 35–59 years without dysglycemia, depending on the presence of arterial hypertension (AH).</italic></p> <p><bold><italic>Methods.</italic></bold><italic> Body mass index (BMI), waist circumference (WC), blood pressure, triglycerides, HDL-C, IRI, FSH and estradiol levels, fasting glycemia, TyG and HOMA2 family indices were determined in 88 normoglycemic women aged 35–59 years with different functional state of the pituitary-ovarian axis and divided into 2 groups depending on the presence of arterial hypertension. Using SPSS (version 17), ME (25–75%); intergroup differences according to the Mann-Whitney test assessed; Spearman rank correlation analysis and partial correlation analysis to level the influence of age were carried out.</italic></p> <p><bold><italic>Results.</italic></bold><italic> The largest range of significant associations, independent of age and in tandem with it, in contrast to the HOMA2 family indices, was found in TyG in the group of patients with arterial hypertension: with WC and BMI, IRI and HDL-C, FSH and E2. The TyG index is also influenced by age-associated factors: the duration of arterial hypertension and postmenopause. In the general cohort of women (n=88), most of these correlations persist and increase, but associations with FSH and E2 persist only within the Spearman analysis. Stable associations of TyG with IRI in the absence of those with HOMA2-B in patients with hypertension without dysglycemia attract attention.</italic></p> <p><bold><italic>Conclusion.</italic></bold><italic> In the process of the formation of menopausal MS in patients with AH, the TyG index, in contrast to HOMA2-IR and HOMA2-S, forms a greater number of stable age-associated an age-independent correlations with MS markers and indicators of the functional activity of the pituitary-ovarian axis during the period of menopausal transition. Correlations of TyG with RI levels, which are stable when the effect of age is leveled in patients with AH without dysglycemia, indicate the threat of carbohydrate metabolism disorders through the phenomenon of lipoglucotoxicity with a further increase in RI against the background of estrogen deficiency.</italic></p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Актуальность. </italic></bold><italic>Необходимость оценки инсулинорезистентности (ИР), патогенетически объединяющей компоненты метаболического синдрома (МС), приобретает особое значение при его формировании в период менопаузального перехода вследствие изменения функционального состояния оси гипофиз–яичники. В качестве суррогатных показателей, наряду с традиционными индексами семейства HOMA, в последние годы привлекает внимание индекс TyG, показавший тесную согласованность с клэмп-тестом, «золотым» стандартом оценки тяжести ИР. Однако сравнительные исследования информативности суррогатных инсулиновых и неинсулиновых индексов в перименопаузальный период практически отсутствуют.</italic></p> <p><bold><italic>Цель исследования:</italic></bold><italic> оценить влияние возраста на взаимосвязи суррогатных индексов ИР, </italic><italic>TyG</italic><italic> и семейства </italic><italic>HOMA</italic><italic>2 с параметрами менопаузального МС в процессе его формирования в когорте женщин 35–59 лет без дисгликемии в зависимости от наличия артериальной гипертензии (АГ).</italic></p> <p><bold><italic>Методы.</italic></bold><italic> У 88 нормогликемических женщин 35–59 лет с различным функциональным состоянием оси гипофиз–яичники и разделенных на 2 группы в зависимости от наличия АГ определены индекс массы тела (ИМТ), окружность талии (ОТ), уровни артериального давления, триглицеридов, ХС-ЛПВП, ИРИ, ФСГ и эстрадиола, гликемии натощак, индексы </italic><italic>TyG</italic><italic> и семейства </italic><italic>HOMA</italic><italic>2. С помощью </italic><italic>SPSS</italic><italic> (версия 17) оценивали </italic><italic>ME</italic><italic> (25–75%); межгрупповые различия по критерию </italic><italic>Mann</italic><italic>–</italic><italic>Whitn</italic><italic>е</italic><italic>y</italic><italic>; проводили корреляционные анализы по Спирмену и частичный для нивелирования влияния возраста.</italic></p> <p><bold><italic>Результаты.</italic></bold><italic> Наибольший спектр значимых ассоциаций, не зависимых от возраста и в тандеме с ним в отличие от индексов семейства </italic><italic>HOMA</italic><italic>2 выявлен у </italic><italic>TyG</italic><italic> в группе пациенток с АГ: с ОТ и ИМТ, ИРИ и ХС-ЛПВП, ФСГ и Е2. На индекс </italic><italic>TyG</italic><italic> также оказывают влияние возраст-ассоциированные факторы: длительность АГ и постменопаузы. В общей когорте женщин (</italic><italic>n</italic><italic>=88) большинство указанных корреляционных связей сохраняется и усиливается, однако ассоциации с ФСГ и Е2 сохраняются только в рамках анализа по Спирмену. Обращают внимание стабильные ассоциации </italic><italic>TyG</italic><italic> с ИРИ в отсутствие таковых с </italic><italic>HOMA</italic><italic>2-</italic><italic>B</italic><italic> у пациенток с АГ без дисгликемии.</italic></p> <p><bold><italic>Заключение.</italic></bold><italic> В процессе формирования менопаузального МС у пациенток с АГ индекс </italic><italic>TyG</italic><italic> в отличие от </italic><italic>HOMA</italic><italic>2-</italic><italic>IR</italic><italic> и </italic><italic>HOMA</italic><italic>2-</italic><italic>S</italic><italic> образует большее число стабильных корреляционных связей, ассоциированных с возрастом и не зависимых от него, с маркерами МС и показателями функциональной активности оси гипофиз–яичники в период менопаузального перехода. Корреляции </italic><italic>TyG</italic><italic> с уровнями ИРИ, стабильные при нивелировании влияния возраста у пациенток с АГ без дисгликемии, свидетельствуют об угрозе нарушений углеводного обмена через феномен липоглюкотоксичности при дальнейшем усилении ИР на фоне эстрогенного дефицита.</italic></p></trans-abstract><kwd-group xml:lang="en"><kwd>TyG index</kwd><kwd>HOMA2 family indices</kwd><kwd>menopausal metabolic syndrome</kwd><kwd>insulin resistance</kwd><kwd>arterial hypertension</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>индекс TyG</kwd><kwd>индексы семейства HOMA2</kwd><kwd>менопаузальный метаболический синдром</kwd><kwd>инсулинорезистентность</kwd><kwd>артериальная гипертензия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Tune J.D., Goodwill A.G., Sassoon D.J., Mather K.J. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017;183:57–70. Doi: 10.1016/j.trsl.2017.01.001.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Lindberg S., Jensen J.S., Bjerre M., et al. Low adiponectin levels at baseline and decreasing adiponectin levels over 10 years of follow-up predict risk of the metabolic syndrome. Diabetes Metab. 2017;43(2):134–39. Doi: 10.1016/j.diabet.2016.07.027.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Lopez-Jaramillo P., Gomez-Arbelaez D., Martinez-Bello D., et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023;4(1):e23–e33. Doi: 10.1016/S2666-7568(22)00247-1.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Reaven G.M. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin N Am. 2004;33:283–303. Doi: 10.1016/j.ecl.2004.03.002.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Alberti K.G., Eckel R.H., Grundy S.M., et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–45. Doi: 10.1161/CIRCULATIONAHA.109.192644.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Jeong H.G., Park H. Metabolic Disorders in Menopause. Metabolites. 2022;12(10):954. Doi: org/10.3390/metabo12100954.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Fisher G., Tay J., Warren J.L., et al. Sex and race contribute to variation in mitochondrial function and insulin sensitivity. Physiol Rep. 2021;9(19):e15049. Doi: 10.14814/phy2.15049.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Oya J., Nakagami T., Yamamoto Y., Fukushima S. et al. Effects of age on insulin resistance and secretion in subjects without diabetes. Intern Med. 2014;53(9):941–47. Doi: 10.2169/internalmedicine.53.1580.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ahmed F., Kamble P.G., Hetty S., et al. Role of Estrogen and Its Receptors in Adipose Tissue Glucose Metabolism in Pre- and Postmenopausal Women. J Clin Endocrinol Metab. 2022;107(5):e1879-e1889. Doi: 10.1210/clinem/dgac042.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Stevenson J.C., Tsiligiannis S., Panay N. Cardiovascular Risk in Perimenopausal Women. Curr Vasc Pharmacol. 2019;17(6):591–594. Doi: 10.2174/1570161116666181002145340.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Kodoth V, Scaccia S, Aggarwal B. Adverse Changes in Body Composition During the Menopausal Transition and Relation to Cardiovascular Risk: A Contemporary Review. Womens Health Rep (New Rochelle). 2022;3(1):573–81. Doi: 10.1089/whr.2021.0119.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Park S.K., Harlow S.D., Zheng H., et al. Association between changes in oestradiol and follicle-stimulating hormone levels during the menopausal transition and risk of diabetes. Diabet Med. 2017;34(4):531–38. Doi: org/10.1111/dme.13301.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Son M.K., Lim N.K., Lim J.Y., et al. Difference in blood pressure between early and late menopausal transition was significant in healthy Korean women. BMC Womens Health. 2015;15:64. Doi: 10.1186/s12905-015-0219-9.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Malmstrom H., Walldius G., Carlsson S., et al. Elevations of metabolic risk factors 20 years or more before diagnosis of type 2 diabetes: Experience from the AMORIS study. Diabetes Obes Metab. 2018;20(6):1419–26. Doi: 10.1111/dom.13241.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Garvey W.T., Garber A.J., Mechanick J.I., et al. The Aace Obesity Scientific Committee. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977-89. Doi: 10.4158/EP14280.PS.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A., et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. Doi: 10.1016/j.maturitas.2018.08.009.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Руяткина Л.А., Руяткин Д.С., Исхакова И.С. Возможности и варианты суррогатной оценки инсулинорезистентности. Ожирение и метаболизм. 2019;16(1):27–33. [Ruyatkina L.A., Ruyatkin D.S., Iskhakova I.S. Opportunities and options for surrogate assessment of insulin resistance. Ozhirenie i metabolizm=Obesity and metabolism. 2019;16(1):27–33. (In Russ.)]. Doi: 10.14341/omet10082.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Guerrero-Romero F., Simental-Mendia L.E., Gonzalez-Ortiz M., et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–51. Doi: 10.1210/jc.2010-0288.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Massimino M., Monea G., Marinaro G., et al. The Triglycerides and Glucose (TyG) Index Is Associated with 1-Hour Glucose Levels during an OGTT. Int J Environ Res Public Health. 2022;20(1):787. Doi: 10.3390/ijerph20010787.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Клинические рекомендации. Менопауза и климактерическое состояние у женщин. 2021. [Clinical guidelines. Menopause and menopause in women. 2021. (In Russ.)]. URL: https://minzdrav.orb.ru/documents/active/33083/.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Wallace T.M., Levy J.C., Matthews D.R. Use and Abuse of HOMA Modeling. Diabetes Care. 2004;27(6):1487–95. Doi: 10.2337/diacare.27.6.1487.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Karvonen-Gutierrez C., Kim C. Association of Mid-Life Changes in Body Size, Body Composition and Obesity Status with the Menopausal Transition. Healthcare (Basel). 2016;4(3):42. Doi: 10.3390/healthcare4030042.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Randolph J.F. Jr., Zheng H., Sowers M.R., et al. Change in Follicle-Stimulating Hormone and Estradiol Across the Menopausal Transition: Effect of Age at the Final Menstrual Period. J Clin Endocrin &amp; Metab. 2011;96(3):746–74. Doi: 10.1210/jc.2010-1746.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Yu Z., Yang J., Huang, W.J., et al. Follicle stimulating hormone promotes production of renin through its receptor in juxtaglomerular cells of kidney. Diabetol Metab Syndr. 2022;14(1):65. Doi: 10.1186/s13098-022-00816-x.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Barton M., Meyer M.R. Postmenopausal Hypertension: Mechanisms and Therapy. Hypertension. 2009;54(1):11–8. Doi: 10.1161/HYPERTENSIONAHA.108.120022.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Руяткина Л.А., Руяткин Д.С. Ожирение: «перекрестки» мнений, знаний и возможностей. Медицинский Совет. 2020;(7):108-120. [Ruyatkina L.A., Ruyatkin D.S. Obesity: The Crossroads of Opinion, Knowledge, and Opportunity. Meditsinskiy sovet=Medical Council. 2020;(7):108–20. (In Russ.)]. Doi: 10.21518/2079-701X-2020-7-108-120.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Lopez-Lopez J.P., Cohen D.D., Ney-Salazar D., et al. The prediction of Metabolic Syndrome alterations is improved by combining waist circumference and handgrip strength measurements compared to either alone. Cardiovasc Diabetol. 2021;20(1):68. Doi: 10.1186/s12933-021-01256-z.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Karakelides H., Irving B.A., Short K.R., O’Brien P., Nair KS. Age, obesity, and sex effects on insulin sensitivity and skeletal muscle mitochondrial function. Diabetes. 2010;59(1):89–97. Doi: 10.2337/db09-0591.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Exebio J.C., Ajabshir S., Zarini G.G., et al. Use of Homeostatic Model Assessment Indexes for the Identification of Metabolic Syndrome and Insulin Resistance among Cuban-Americans: A Cross Sectional Study. Br J Med Med Res. 2014;4(29):4824–33. Doi: 10.9734/BJMMR/2014/8988.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Wu Z., Cui H., Li W., et al. Comparison of three non-insulin-based insulin resistance indexes in predicting the presence and severity of coronary artery disease. Front Cardiovasc Med. 2022;29(9):918359. Doi: 10.3389/fcvm.2022.918359.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Cerf M.E. Developmental Programming and Glucolipotoxicity: Insights on Beta Cell Inflammation and Diabetes. Metabolites. 2020;10(11):444. Doi: 10.3390/metabo10110444.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Lee Y., Hirose H., Ohneda M., Johnson J.H. et al. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A. 1994;91(23):10878–82. Doi: 10.1073/pnas.91.23.10878.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Somesh B.P., Verma M.K., Sadasivuni M.K., et al. Chronic Glucolipotoxic Conditions in Pancreatic Islets Impair Insulin Secretion Due to Dysregulated Calcium Dynamics, Glucose Responsiveness and Mitochondrial Activity. BMC Cell Biol. 2013;14:31. Doi: 10.1186/ 1471-2121-14-31.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Руяткина Л.А., Руяткин Д.С., Исхакова И.С. Анализ формирования дисгликемии в обосновании ранней патогенетической терапии сахарного диабета. Медицинский совет. 2021;(7):33–44. [Ruyatkina L.A., Ruyatkin D.S., Iskhakova I.S. Analysis of the formation of dysglycemia in the substantiation of early pathogenetic therapy of diabetes mellitus. Meditsinskiy sovet=Medical Council. 2021;(7):33–44. (In Russ.)]. Doi: 10.21518/2079-701X-2021-7-33-44.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Li X., Li G., Cheng T., et al. Association between triglyceride-glucose index and risk of incident diabetes: a secondary analysis based on a Chinese cohort study: TyG index and incident diabetes. Lipids Health Dis. 2020;19(1):236. Doi: 10.1186/s12944-020-01403-7.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Lee D.Y., Lee E.S., Kim J.H., Park S.E. et al. Predictive Value of Triglyceride Glucose Index for the Risk of Incident Diabetes: A 4-Year Retrospective Longitudinal Study. PLoS One. 2016;11(9):e0163465. Doi: 10.1371/journal.pone.0163465.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Wang Q., Jokelainen J., Auvinen J., et al. Insulin resistance and systemic metabolic changes in oral glucose tolerance test in 5340 individuals: an interventional study. BMC Med. 2019;17(1):217. Doi: 10.1186/s12916-019-1440-4.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Abdul-Ghani M.A., Abdul-Ghani T., Ali N., Defronzo R.A. One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care. 2008;31(8):1650–55. Doi: 10.2337/dc08-0225.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Correia E.S., Godinho-Mota J.C.M., Schincaglia R.M., et al. Metabolic Syndrome in postmenopausal women: prevalence, sensibility, and specificity of adiposity indices. Clinical Nutrition Open Science. 2022;41:106–14. Doi: org/10.1016/j.nutos.2022.01.001</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Seghieri M., Trico D., Natali A. The impact of triglycerides on glucose tolerance: Lipotoxicity revisited. Diabetes Metab. 2017;43(4):314–22. Doi: org/10.1016/j.diabet.2017.04.010.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Agarwal T., Lyngdoh T., Dudbridge F., et al. Causal relationships between lipid and glycemic levels in an Indian population: A bidirectional Mendelian randomization approach. PLoS One. 2020;15(1):e0228269. Doi: 10.1371/journal.pone.0228269.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Yu W., Zhou G., Fan B., et al. Temporal sequence of blood lipids and insulin resistance in perimenopausal women: the study of women’s health across the nation. BMJ Open Diab Res Care. 2022;10(2):e002653. Doi: 10.1136/bmjdrc-2021-002653.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Mahdavi-Roshan M., Shoaibinobarian N.., Noormohammadi M, et al. Inflammatory Markers and Atherogenic Coefficient: Early Markers of Metabolic Syndrome. Int J Endocrinol Metab. 2022;20(4):e127445. Doi: 10.5812/ijem-127445.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Pang S., Miao G., Zhou Y., et al. Addition of TyG index to the GRACE score improves prediction of adverse cardiovascular outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: A retrospective study. Front Cardiovasc Med. 2022;9:957626. Doi: 10.3389/fcvm.2022.957626.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Lipke K., Kubis-Kubiak A., Piwowar A. Molecular Mechanism of Lipotoxicity as an Interesting Aspect in the Development of Pathological States-Current View of Knowledge. Cells. 2022;11(5):844. Doi: 10.3390/cells11050844.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Cho A.R., Kwon Y.J., Kim J.K. Pre-Metabolic Syndrome and Incidence of Type 2 Diabetes and Hypertension: From the Korean Genome and Epidemiology Study. J Pers Med. 2021;11(8):700. Doi: 10.3390/jpm11080700.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Strack C., Behrens G., Sag S., et al. Gender differences in cardiometabolic health and disease in a cross-sectional observational obesity study. Biol Sex Differ. 2022;13(1):8. Doi: 10.1186/s13293-022-00416-4.</mixed-citation></ref></ref-list></back></article>
